A panoramic perspective of recent progress in 2D and 3D covalent organic frameworks for drug delivery

Abstract

The development of efficient drug delivery systems is essential for improving the efficacy and safety of cancer drugs, particularly for aggressive and difficult‐to‐treat cancers. Covalent organic frameworks (COFs) are emerging as innovative porous nanomaterials in drug delivery systems (DDS), due to their unique properties, including the metal‐free organic skeleton, predetermined structures and pore geometries, high porosity, large surface area, facile surface modification potential, and good biocompatibility. These characteristics make COFs excellent candidates for improving drug delivery by enhancing drug loading capacity and enabling precise encapsulation. This review emphasizes the importance of donor‐acceptor‐based COFs, which provide channels for charge transportation, and we also explore how the π‐conjugated skeleton of COFs enhances its long‐acting fluorescent properties and facilitates drug uptake via cell endocytosis. While this review primarily focuses on recent advancements in COF‐based targeted DDS, it also acknowledges the challenges posed by the diverse pore geometries in porous materials and discusses potential solutions. Further, it underlines the potential of developing future drug carriers that can successfully and specifically target cancer cells, improving treatment efficiency while reducing adverse side effects.

Covalent Organic Frameworks as Potential Drug Carriers and Chemotherapeutic Agents for Ovarian Cancers

“…The desirable properties of COFs, which include but are not limited to facile synthesis and drug loading, enhanced optical capabilities and biocompatibility, and controlled drug delivery, increase their potential as futuristic materials for sarcoma treatment . In the scientific literature, there are reports of only a handful of COFs that have been explored as potential carriers of chemotherapeutic drugs such as doxorubicin (DOX), carboplatin, and cisplatin. ,− However, COFs have not been explored as a carrier for paclitaxel (PTX), a chemotherapeutic drug used for the treatment of ovarian cancer. In this regard, herein a set of nine imine or β-ketoimine linkage COFs has been synthesized for their use as drug-delivery agents for chemotherapeutic applications.…”